Back in June, we told you about the early results of the LATITUDE clinical trial, presented at the 2017 ASCO conference. The study indicated that giving abiraterone in combination with low-dose prednisone to men who were just starting ADT delayed cancer progression by an average of 18 months. The study also showed that this same protocol reduced the risk of death by 38% compared to a placebo group.
The 2018 Patient Guide is here
Enter your email address to get the free pdf
Now, less than a year later, the U.S. Food and Drug Administration has approved this combination for men with metastatic high-risk castration-sensitive prostate cancer (CSPC). The approval is based on the results of the LATITUDE study.
PCF was instrumental in funding the early stage trial that led to the development of abiriaterone, and eventually its FDA approval in 2011.
For more information on this latest approval can be found here.
The results of the original LATITUDE Trial were published in 2017 in the New England Journal of Medicine.
Terms to know from this article:
Abiraterone acetate (Zytiga) is an oral medication that blocks the synthesis of androgens (male hormones), such as testosterone, inside the tumor. Abiraterone is FDA approved for the treatment of patients with metastatic castrate resistant prostate cancer.
Increase in the size of a tumor or spread of cancer in the body.
An inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.